Area of research
Genetics · Epidemiology
Research interest
Research interests include Inflammatory Bowel Disease, Microscopic Colitis, Multiple Myeloma Research and Treatments, and Pluripotent Stem Cells Research.
LGR4 promotes proliferation and homing via activation of the NF‑κB signaling pathway in multiple myeloma
Biomarkers of pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis through single-cell transcriptomics.
Targeting the origins of multiple myeloma along hematopoietic stem cell lymphoid lineage differentiation.
Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma.
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma
A Comparative Evaluation of the Measurement Properties of Three Histological Indices of Mucosal Healing in Ulcerative Colitis: Geboes Score, Robarts Histopathology Index and Nancy Index
Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma.
Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis
Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data
The Interaction between Gut Microbiota and Host Amino Acids Metabolism in Multiple Myeloma.
Proline promotes proliferation and drug resistance of multiple myeloma by downregulation of proline dehydrogenase.
Intestinal Microbes and Hematological Malignancies.
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment
Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance
Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance.
Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma.
Single-Cell RNA-seq Analysis Reveals Dysregulated Cell-Cell Interactions in a Tumor Microenvironment Related to HCC Development.
OP23 Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study
COX2 confers bone marrow stromal cells to promoting TNFα/TNFR1β-mediated myeloma cell growth and adhesion.
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria.
NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma.
Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma.
Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s
Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s.
Detection of recurrent cytogenetic aberrations in multiple myeloma: A comparison between MLPA and iFISH